These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 27881032

  • 1. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
    Amcoff K, Stridsberg M, Lampinen M, Magnuson A, Carlson M, Halfvarson J.
    Scand J Gastroenterol; 2017 Mar; 52(3):344-350. PubMed ID: 27881032
    [Abstract] [Full Text] [Related]

  • 2. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G.
    Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
    [Abstract] [Full Text] [Related]

  • 3. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
    Kristensen V, Malmstrøm GH, Skar V, Røseth A, Moum B.
    Scand J Gastroenterol; 2016 May; 51(5):548-55. PubMed ID: 26634305
    [Abstract] [Full Text] [Related]

  • 4. A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease.
    Lee JM, Jang JH, Ryu JH, Yoo J, Lee BI, Kim SJ, Oh EJ.
    PLoS One; 2021 May; 16(8):e0255974. PubMed ID: 34383847
    [Abstract] [Full Text] [Related]

  • 5. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G.
    World J Gastroenterol; 2017 Nov 07; 23(41):7387-7396. PubMed ID: 29151692
    [Abstract] [Full Text] [Related]

  • 6. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B.
    J Crohns Colitis; 2015 Feb 07; 9(2):164-9. PubMed ID: 25518057
    [Abstract] [Full Text] [Related]

  • 7. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A.
    Dig Liver Dis; 2014 Nov 07; 46(11):974-9. PubMed ID: 25096964
    [Abstract] [Full Text] [Related]

  • 8. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
    Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN.
    Korean J Intern Med; 2019 Jan 07; 34(1):72-80. PubMed ID: 29347813
    [Abstract] [Full Text] [Related]

  • 9. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J.
    Aliment Pharmacol Ther; 2016 Sep 07; 44(5):495-504. PubMed ID: 27402063
    [Abstract] [Full Text] [Related]

  • 10. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R.
    Health Technol Assess; 2013 Nov 07; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [Abstract] [Full Text] [Related]

  • 11. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ, Ford C, Gama RM, Ali A, McKaig B, Waldron JL, Steed H, Brookes MJ.
    J Clin Pathol; 2017 Dec 07; 70(12):1049-1056. PubMed ID: 28735301
    [Abstract] [Full Text] [Related]

  • 12. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.
    J Crohns Colitis; 2015 Jan 07; 9(1):50-5. PubMed ID: 25518048
    [Abstract] [Full Text] [Related]

  • 13. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.
    Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M.
    Eur J Clin Invest; 2016 Oct 07; 46(10):825-32. PubMed ID: 27438629
    [Abstract] [Full Text] [Related]

  • 14. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
    Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S.
    Inflamm Bowel Dis; 2008 May 07; 14(5):669-73. PubMed ID: 18240279
    [Abstract] [Full Text] [Related]

  • 15. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
    Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.
    Inflamm Bowel Dis; 2014 Feb 07; 20(2):307-14. PubMed ID: 24374878
    [Abstract] [Full Text] [Related]

  • 16. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R.
    Dig Liver Dis; 2008 Jul 07; 40(7):547-53. PubMed ID: 18358796
    [Abstract] [Full Text] [Related]

  • 17. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM, Nisihara RM, Marion SB, Cavassani MF, Kotze PG.
    Arq Gastroenterol; 2015 Jul 07; 52(1):50-4. PubMed ID: 26017083
    [Abstract] [Full Text] [Related]

  • 18. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.
    Kennedy NA, Clark A, Walkden A, Chang JC, Fascí-Spurio F, Muscat M, Gordon BW, Kingstone K, Satsangi J, Arnott ID, Lees CW.
    J Crohns Colitis; 2015 Jan 07; 9(1):41-9. PubMed ID: 25135754
    [Abstract] [Full Text] [Related]

  • 19. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T.
    J Crohns Colitis; 2015 Jan 07; 9(1):33-40. PubMed ID: 25052347
    [Abstract] [Full Text] [Related]

  • 20. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity.
    Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF.
    Clin Gastroenterol Hepatol; 2017 Nov 07; 15(11):1742-1749.e2. PubMed ID: 28606846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.